Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Stomatitis and Bone Marrow Suppression Followed by Leukoerythroblastosis in a Patient on Long-Term Low-Dose Methotrexate Therapy.

The American journal of medicine·2022

Same author

Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia.

The American journal of case reports·2020

Same author

Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature.

Journal of clinical apheresis·2019

Same author

Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.

The American journal of medicine·2019

Same author

Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia.

The American journal of medicine·2018

Same author

In Reply.

Obstetrics and gynecology·2016

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

ADAMTS13 and microvascular thrombosis.

¹Montefiore Medical Center and Albert Einstein College of Medicine, Unified Division of Hematology, Bronx, New York, NY, USA. htsai@montefiore.org

Expert Review of Cardiovascular Therapy

|December 19, 2006

Summary

A deficiency in ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif, number 13) causes thrombotic thrombocytopenic purpura by allowing unregulated platelet-von Willebrand factor interactions. Advances in understanding ADAMTS13 are improving diagnosis and therapy.

More Related Videos

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres

Published on: November 21, 2025

Related Experiment Videos

Last Updated: Jul 18, 2026

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres

Published on: November 21, 2025

Area of Science:

Hematology
Biochemistry
Molecular Biology

Background:

Platelet and von Willebrand factor interaction is crucial for hemostasis under high shear stress.
Unregulated interaction can lead to dangerous platelet thrombosis.
ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif, number 13) regulates this interaction.

Purpose of the Study:

To investigate the role of ADAMTS13 in preventing von Willebrand factor-platelet interaction.
To understand the mechanisms leading to thrombotic thrombocytopenic purpura (TTP).
To explore advances in TTP diagnosis and therapy.

Main Methods:

Cloning of the ADAMTS13 enzyme.
Structure-function analyses of ADAMTS13.
Investigating genetic mutations and autoimmune inhibition of ADAMTS13.

Main Results:

ADAMTS13 cleaves shear stress-activated von Willebrand factor, preventing thrombosis.
Profound deficiency of ADAMTS13 causes TTP.
TTP is characterized by intravascular von Willebrand factor platelet aggregation and microvascular thrombosis.

Conclusions:

ADAMTS13 plays a critical role in preventing thrombotic thrombocytopenic purpura.
Understanding ADAMTS13's function is key to diagnosing and treating TTP.
Advances in enzyme research offer new therapeutic strategies for TTP.